Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Effective testosterone suppression for patients with prostate cancer: is there a best castration?

× No keyword cloud information.

8 in total

1. Stimulation of a non-functioning pituitary macroadenoma after administration of goserelin acetate for locally advanced prostate cancer causing a sustained elevation in PSA and testosterone.

Authors: Fady R Youssef; Robert T Robinson; Nigel R Boucher
Journal: Can Urol Assoc J Date: 2012-04 Impact factor: 1.862

2. Patient rationale in selecting androgen deprivation (PRISAD): do we give patients what they want?

Authors: Eric Chung; Hunter Watt; Amanda Glasgow; Tim Skyring
Journal: Med Oncol Date: 2008-12-04 Impact factor: 3.064

3. A population K-PD model analysis of long-term testosterone inhibition in prostate cancer patients undergoing intermittent androgen deprivation therapy.

Authors: Joost DeJongh; Maurice Ahsman; Nelleke Snelder
Journal: J Pharmacokinet Pharmacodyn Date: 2021-02-04 Impact factor: 2.745

Review 4. Hormone naïve prostate cancer: predicting and maximizing response intervals.

Authors: Judd W Moul
Journal: Asian J Androl Date: 2015 Nov-Dec Impact factor: 3.285

5. Optimal dynamic control approach in a multi-objective therapeutic scenario: Application to drug delivery in the treatment of prostate cancer.

Authors: Itziar Irurzun-Arana; Alvaro Janda; Sergio Ardanza-Trevijano; Iñaki F Trocóniz
Journal: PLoS Comput Biol Date: 2018-04-19 Impact factor: 4.475

Effective testosterone suppression for patients with prostate cancer: is there a best castration?

1. Stimulation of a non-functioning pituitary macroadenoma after administration of goserelin acetate for locally advanced prostate cancer causing a sustained elevation in PSA and testosterone.

2. Patient rationale in selecting androgen deprivation (PRISAD): do we give patients what they want?

3. A population K-PD model analysis of long-term testosterone inhibition in prostate cancer patients undergoing intermittent androgen deprivation therapy.

Review 4. Hormone naïve prostate cancer: predicting and maximizing response intervals.

5. Optimal dynamic control approach in a multi-objective therapeutic scenario: Application to drug delivery in the treatment of prostate cancer.

Review 6. How do we define "castration" in men on androgen deprivation therapy?

7. Overexpression of α (1,6) fucosyltransferase in the development of castration-resistant prostate cancer cells.

Review 8. Definition of Castrate Resistant Prostate Cancer: New Insights.